ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1745

Serum Irisin and Prediction of Cardiovascular Events in Elderly Patients with CKD Stage 3-5

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism

Authors

  • Del Mastro, Teresa, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Arcidiacono, Teresa, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Avino, Monica, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Bologna, Arianna, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Foligno, Nadia Edvige, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Persico, Federico, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Vezzoli, Giuseppe, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
Background

Irisin is a circulating myokine released from skeletal muscles after physical exercise. Irisin production decreases during the course of chronic kidney disease (CKD) as a potential consequence of sarcopenia and physical inactivity.

Methods

This observational study explored the relationship of serum irisin with cardiovascular outcome in 79 patients with stage 3-5 CKD.

Results

Serum irisin was significantly higher in healthy subjects (n=20) than CKD patients (7±2 vs 3.1±0.9 µg/ml; p=0.0001) and was higher in patients with CKD stage 3 (3.2±1 µg/ml) compared with patients at stage 4 and 5 taken together (n=36, 2.8±0.7 µg/ml, p=0.05). Patients in the lowest serum irisin tertile had lower serum 1,25(OH)2D levels (21±11 pg/ml) than patients in the middle (30±13 pg/ml; p=0.005) and the highest tertile (27±14 pg/ml; p=0.047). Patients in the highest tertile had lower Kauppila score (10.6±6.9) than patients in the middle (11.8±5.5; p=0.007) and the lowest tertile (6.9±6.8; p=0.043). Twenty patients suffered from cardiovascular events during a 3-year follow-up. A Cox regression model using age, body weight, presence of diabetes mellitus, gender, Kauppila calcification score, serum values of FGF23 (as logarithm), phosphate, sclerostin, albumin and cholesterol, eGFR and serum irisin tertiles as covariates showed that patients in the highest tertile of serum irisin had a lower cardiovascular risk than patients in the middle tertile (B 2.38, OR 10.8, 95%CI 1.65-58.13; p=0.013) or in the lowest tertile (B 1.61, OR 5, 95%CI 1.09-22.83; p=0.038).

Conclusion

These findings suggest that serum irisin may be a marker of cardiovascular outcome in CKD patients.

Image 1

Image 2